Probiodrug Transfers its CDK9 Inhibitor Program to AstraZeneca

13-01-2014 Business Wire HealthComments (0)

AstraZenecaPharmaceutical

Probiodrug has transferred its experimental CDK9 inhibitor program to AstraZeneca. CDK9 inhibitors are promising targets for the treatment of cancers and inflammatory diseases.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top